Epidermal squamous cell carcinoma is an extremely common type of cancer. Early tumors can be successfully treated by surgery, but recurrent disease is aggressive and resistant to therapy. Cisplatin is often used as a treatment, but the outcome is rarely satisfactory. For this reason new strategies are required. Sulforaphane is a diet-derived cancer prevention agent that is effective in suppressing tumor growth in animal models of skin cancer. We monitored the efficacy of sulforaphane and cisplatin as a combined therapy for squamous cell carcinoma. Both agents suppress cell proliferation, growth of cancer stem cell spheroids, matrigel invasion and migration of SCC-13 and HaCaT cells, and combination treatment is more efficient. In addition, SCC-13 cell derived cancer stem cells are more responsive to these agents than non-stem cancer cells. Both agents suppress tumor formation, but enhanced suppression is observed with combined treatment. Moreover, both agents reduce the number of tumor-resident cancer stem
cells. SFN treatment of cultured cells or tumors increases apoptosis and p21
Cip1 level, and both agents increase tumor apoptosis. We suggest that combined therapy with sulforaphane and cisplatin is efficient in suppressing tumor formation and may be a treatment option for advanced epidermal squamous cell carcinoma.
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| INTRODUCTION
Epidermal squamous cell carcinoma is a leading cause of cancer that is routinely treated by surgical resection. 1 However, nearly 10% of these cancers recur as highly aggressive and invasive cancers that must be treated with chemotherapy. 2, 3 Cisplatin, doxorubicin, 5-fluorouracil, and bleomycin have been used to treat this disease 2 ; however, chemoresistance is an important problem. 2, 4 Designing strategies to overcome chemotherapy resistance is an important goal. The clinical scenario suggests that a subset of tumor cells are unaffected by therapy and are able to initiate formation of a new tumor. Considering that tumors are complex "organs" comprising many tumor cell variants, it is plausible that therapy resistance is related to a subpopulation of less differentiated, multipotent, self-renewing, and aggressive cancer stem cells. 5, 6 Current therapies often target the highly proliferative tumor cells to reduce tumor bulk, but these agents do not always kill cancer stem cells. [7] [8] [9] [10] Squamous cell carcinoma contains a population of cells that are able to self-renew. [11] [12] [13] [14] Our recent studies confirm that a highly 
| Proliferation assay
SCC-13 cells were grown for 1 week as monolayers in spheroid media.
Cells were harvested with 0.25% trypsin, resuspended in spheroid medium and grown as monolayer cultures. At 24 h after plating, treatment was initiated with SFN or cisplatin or appropriate vehicle.
Cells were harvested at various times and cell number was counted using a Z1 Coulter Particle Counter (Beckman Coulter). Figures 1E and 1F ).
| Invasion assay

| Impact of SFN and cisplatin on ECS cell invasion and migration
ECS cell invasion and migration, are enhanced in ECS cells as compared to non-stem cancer cells. 15, 17 We therefore monitored the impact of cisplatin and SFN on ECS cell invasion and migration. Cells (25 000) were plated in a Transwell chamber atop a matrigel-coated membrane and then treated with 0.5 μM SFN, 0.5 μM cisplatin or both agents. After 18 h, the membrane was stained to detect cells that had invaded through the matrigel to the lower chamber. Figure 1G shows that SFN and cisplatin reduce cell invasion, and that combined treatment further reduces invasion. We repeated this experiment using higher concentrations of each agent. Figures 1H and 1I show that 5 μM SFN and 1 μM cisplatin produce a more substantial reduction in matrigel invasion.
However, the combination treatment is more efficient. To study cell migration, ECS cells were seeded at confluent density in monolayer culture, wounds were created by scraping with a pipette tip and wound closure was monitored from 0 to 24 h. As shown in Figure 1J , cisplatin and SFN treatment reduce wound closure as does combined treatment.
| Impact of SFN and cisplatin on tumor formation
We next examined the impact of cisplatin and SFN on tumor formation. Figure 3E ). We next monitored the impact on cell invasion and migration. Figures 3F and 3G show that both agents suppress matrigel invasion and that combined treatment further suppresses invasion. Figure 3G shows that each agent suppresses HaCaT cell migration. tumors. 1 In fact, 55% of grade 4 disease is not cured by Moh's surgery SFN is an important cancer prevention/therapy agent derived from cruciferous vegetables (broccoli, etc.). 18, 36, 37 SFN was selected for the present studies because it has efficacy against skin cancer in several model systems, 36, 38 has high bioavailability in vivo 22 and is known to protect against skin cancer induction. 23, 36, 38 Moreover, it
SCC-13 cell-derived ECS
can be detected at bioactive levels in blood and tissues of 43 However, it is possible that cisplatin may permit these cells to escape G2/M arrest leading to premature entry into mitosis and death. 43 In this context, the cells would not arrest in G2/M and p21
Cip1 accumulation would not be observed.
| Impact of SFN and cisplatin on tumor formation
Tumor xenograft studies show that cisplatin and SFN reduce tumor formation. Cisplatin (2 mg/kg) and SFN (25 μmole/dose) markedly [32] [33] [34] These studies show that both cisplatin and SFN reduce spheroid number suggesting that these agents deplete the ECS cell population in the tumor. This is in contrast to some studies which suggest that treatment with agents like cisplatin can positively enrich for cancer stem cells. [32] [33] [34] However, it should be noted that in many studies cisplatin selection of cancer stem cells required serial passage of the cancer cells in mice under continuous drug selective pressure. [32] [33] [34] SFN is a promising candidate agent to consider for co-therapy. It has efficacy against skin cancer in several model systems, 36, 38 is highly bioavailable in vivo, 22 can protect against skin cancer induction and has no known side effects. 23, 36, 38 Our findings suggest that SFN/cisplatin combination may be a useful therapy in squamous cell carcinoma.
